Vaccins tegen SARS-CoV-2

Anke L W Huckriede*

*Bijbehorende auteur voor dit werk

OnderzoeksoutputAcademicpeer review

2086 Downloads (Pure)

Samenvatting

Since the first reports in mid-January of a serious new viral respiratory infection, COVID-19, and the identification of SARS-CoV-2 as the cause of this disease, researchers work intensely on developing a vaccine that can protect individuals against serious disease and that can limit the spread of the virus. Vaccine developers are using a range of platform technologies to do this, each with advantages and disadvantages. Close to 30 vaccines are now in clinical testing. The first results are encouraging, but in order to properly assess the merits of the different vaccines, we must wait for the results of phase 3 trials. The first phase 3 trials have started in July 2020.

Vertaalde titel van de bijdrageSARS coronavirus-2 vaccines: options and state-of-the-art
Originele taal-2Dutch
ArtikelnummerD5352
Aantal pagina's7
TijdschriftNederlands Tijdschrift voor Geneeskunde
Volume164
Nummer van het tijdschrift37
StatusPublished - 3-sep-2020

Keywords

  • Betacoronavirus
  • Clinical Trials, Phase III as Topic
  • Coronavirus Infections/prevention & control
  • Global Health
  • Humans
  • Pandemics/prevention & control
  • Pneumonia, Viral/prevention & control
  • Viral Vaccines

Citeer dit